Insights
Search Results
Client Highlights
5.13.26
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing
On May 13, 2026, Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate cancer treatments, announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses. The PIPE financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, as well as members of the company’s executive team. Wilson Sonsini Goodrich & Rosati advised Whitehawk on the transaction.
Podcasts
5.07.26
NextGen VC Podcast - Building Biotech Companies from Day One: Aimee Raleigh of Atlas Venture
What does it actually take to turn an idea into a biotech company? In the latest episode of the NextGen VC Podcast, Aimee Raleigh, Ph.D., principal at Atlas Venture, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to explore how companies get built before they’re even companies.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
Podcasts
4.09.26
NextGen VC Podcast – From Scalpel to Term Sheet: Rich Gaster of venBio
In the latest episode of the NextGen VC Podcast, Rich Gaster, M.D., Ph.D., managing partner at venBio, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss what it takes to go from performing reconstructive plastic surgeries at Harvard to becoming a managing partner at one of biotech’s most focused venture firms. He traces a career path that runs through Stanford M.D.-Ph.D. training, two grad school start-ups, the company-building engine at Third Rock Ventures, and the founding team of Pliant Therapeutics before landing at venBio, where he helped engineer three back-to-back acquisitions in a single quarter.
Client Highlights
3.31.26
Wilson Sonsini Advises NexCure on $19 Million Series A Financing
On March 5, 2026, NexCure, a healthcare company with a mission to deliver CAR-T and other clinically intensive treatments in community-based outpatient settings, launched with a $19 million Series A financing. The financing was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures. Wilson Sonsini Goodrich & Rosati advised NexCure on the transaction.
Podcasts
3.30.26
NextGen VC Podcast: Dr. Anna French of Qiming Venture Partners
In the latest episode of the NextGen VC Podcast, Dr. Anna French, managing partner at Qiming Venture Partners USA, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to trace her non-linear path from an Oxford D.Phil. and Boston Consulting Group boardrooms to becoming employee No. 1 at one of biotech’s most globally connected venture firms.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Podcasts
2.06.26
NextGen VC Podcast: Suan Tuang on Investing Across Private and Public Biotech
In the latest episode of the NextGen VC Podcast, hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang sit down with Suan Tuang, M.D., Ph.D. Suan didn’t take a traditional path into biotech investing, and his journey shapes how he evaluates risk today. Now at TCG Crossover, Suan brings a clinician-scientist lens to investing across private and public markets. In this episode—available on YouTube—Suan shares how his immigrant journey and academic challenges at MIT and Harvard have shaped his unique approach to risk and resilience. He discusses how he leverages clinical data over hype, balances scientific rigor with market realities, and more. Suan also offers practical advice for aspiring investors and entrepreneurs.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Podcasts
1.16.26
NextGen VC Podcast: A Conversation with Third Rock’s Noreen Rizvi
In the latest episode of the NextGen VC Podcast, hosts and Wilson Sonsini partners Mike Hostetler and Jen Fang sit down with Noreen Rizvi, Ph.D., Principal at Third Rock Ventures, whose journey from chemical engineering to venture creation offers a rare look inside the art and science of biotech investing. Noreen discusses how she bridges science and strategy, what she’s learned from building companies like Trace Neuro and Faze Medicine, and why Third Rock spends years incubating ideas before launch. She also shares how mentorship, collaboration, and a “take the call” mindset have shaped her path. This episode provides a grounded, inside look at company creation, risk-taking, and the evolving biotech landscape from RNA therapeutics to the next generation of life science innovation.
Client Highlights
11.24.25
Wilson Sonsini Advises Bambusa Therapeutics on Series A-2 Financing
On November 17, 2025, Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), announced the completion of its oversubscribed Series A-2 financing at a substantial valuation step-up over the prior round, with participation from Bambusa's existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma (an investment platform controlled by KKR). Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.
Client Highlights
10.02.25
Wilson Sonsini Advises BeSound on $6.8 Million Financing
On September 30, 2025, BLOCH Quantum Imaging Solutions, Inc. (dba BeSound), a pioneering healthcare technology company revolutionizing breast cancer detection, announced it has raised $6.8 million from investors, including Overwater Ventures, Kindred Ventures, Muse Capital, Lux Capital, Wisdom.VC, Retron VC, Mana Ventures, Pave Health Ventures, SSC Venture Partners, Hyperplane VC, and Tom Hale, the CEO of Oura. Wilson Sonsini Goodrich & Rosati advised BeSound on the transaction.
Podcasts
9.11.25
NextGen VC Podcast: Dr. Tia Lyles-Williams on Biotech Innovation and Mentorship
In the latest episode of the NextGen VC Podcast, hosts and Wilson Sonsini partners Jen Fang and Mike Hostetler are joined by Dr. Tia Lyles-Williams, a trailblazer in the biotech industry. Dr. Lyles-Williams shares how mentorship shaped her path, the challenges she overcame, and her vision for inclusive biotech innovation through her accelerator, HiveBio, a first-of-its-kind virtual accelerator program that provides life science entrepreneurial support and resources to minority-owned start-ups. She also provides insights on building a community-driven biotech ecosystem and the importance of perseverance in the face of obstacles. The conversation highlights the dynamic world of venture capital and biotech in Philadelphia.